In 2016, Canadian International Pharma Corp. entered into an agency agreement with a Canadian based pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products (the "Manufacturer"), to sell and market a number of generic and over the counter ("OTC") medications (the "Products") in Canada, and in connection therewith, the Manufacturer has recently obtained required approvals for selling certain of its Products in Canada. The Agreement permits CIPC to generate sales of the Products in the Provinces of British Columbia, Alberta and Saskatchewan, with additional territories under review. Initially, CIPC will be marketing a variety of the Products, including such generic medications as Anastrozole (breast cancer treatment), Citalopram (depression), Letrozole (breast cancer), Ondansetron (nausea from cancer treatment), Rizatriptan Odt (migraine) and Zolmitriptan (migraine), as well as certain over the counter products, such as Bisacodyl (laxative), Comfilax (herbal product for digestion and constipation) and Hot Lemon Relief (cold and flu relief). Additionally, the Company has the potential opportunity of marketing other products as the Manufacturer receives DIN registrations for such medications. In light of the above developments, the Company will be actively presenting the Products to a number of chain and independent pharmacies located in British Columbia, Alberta and Saskatchewan in an effort to obtain 2018 product placements and listings for such Products.